HighTower Advisors LLC increased its position in Celgene Corporation (NASDAQ:CELG) by 22.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 286,119 shares of the biopharmaceutical company’s stock after buying an additional 53,242 shares during the period. HighTower Advisors LLC’s holdings in Celgene Corporation were worth $35,515,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bridges Investment Management Inc. increased its stake in shares of Celgene Corporation by 2.8% in the first quarter. Bridges Investment Management Inc. now owns 134,645 shares of the biopharmaceutical company’s stock worth $16,755,000 after buying an additional 3,622 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its stake in shares of Celgene Corporation by 3.2% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 720,403 shares of the biopharmaceutical company’s stock worth $89,640,000 after buying an additional 22,612 shares during the last quarter. Burns J W & Co. Inc. NY increased its stake in shares of Celgene Corporation by 44.8% in the first quarter. Burns J W & Co. Inc. NY now owns 43,134 shares of the biopharmaceutical company’s stock worth $5,367,000 after buying an additional 13,343 shares during the last quarter. CENTRAL TRUST Co increased its stake in shares of Celgene Corporation by 1.1% in the first quarter. CENTRAL TRUST Co now owns 101,225 shares of the biopharmaceutical company’s stock worth $12,595,000 after buying an additional 1,071 shares during the last quarter. Finally, Independence Advisors LLC acquired a new stake in shares of Celgene Corporation during the first quarter worth $205,000. Institutional investors own 78.41% of the company’s stock.

Celgene Corporation (CELG) traded up 0.18% on Friday, reaching $130.61. The company’s stock had a trading volume of 2,735,623 shares. The stock has a market cap of $102.18 billion, a PE ratio of 40.45 and a beta of 1.89. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The company’s 50 day moving average price is $134.14 and its 200-day moving average price is $124.30.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the previous year, the business earned $1.44 earnings per share. The company’s revenue was up 18.7% on a year-over-year basis. On average, equities analysts expect that Celgene Corporation will post $7.32 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “HighTower Advisors LLC Has $35.52 Million Stake in Celgene Corporation (NASDAQ:CELG)” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/13/hightower-advisors-llc-has-35-52-million-stake-in-celgene-corporation-nasdaqcelg.html.

A number of brokerages have weighed in on CELG. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 target price on shares of Celgene Corporation in a report on Wednesday. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a report on Friday, July 14th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price for the company in a report on Thursday. Finally, Stifel Nicolaus began coverage on Celgene Corporation in a report on Friday, July 28th. They issued a “buy” rating and a $155.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. Celgene Corporation presently has a consensus rating of “Buy” and a consensus target price of $147.00.

In related news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the completion of the sale, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock valued at $31,377,042 in the last 90 days. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.